
14.2.2 Secondary endpoints

14.2.2.9 Incidence of Disease-related mortality

Figure 14.2.2.9.1: Cumulative incidence of Disease-related mortality and relapse from eligibility - Full Analysis Population



ContRuxo: Ruxolitinib continuous therapy. SCT: Allogeneic stem cell transplantation.

Table 14.2.2.9.1: Cumulative incidence of Disease-related mortality and Relapse at 3 years after start of investigational treatment - Full Analysis Population

Timepoint	Event	Treatment arm	Cumulative incidence Function Estimate	Standard Error	95% Lower confidence interval	95% Upper confidence interval
3 years	Disease-related mortality	ContRuxo	0.171	0.119	0.022	0.442
		SCT	0.093	0.040	0.034	0.190
	Relapse	ContRuxo	0.400	0.149	0.131	0.662
		SCT	0.099	0.043	0.036	0.202

ContRuxo: Ruxolitinib continuous therapy. SCT: Allogeneic Stem cell transplantation. Disease-related mortality defined as presence of relapse and occurence of death.
3 years defined as 3 years + 92 days after the date of inclusion to allow for Ruxolitinib induction period. All numerical values are rounded to 3 decimal places.
Page 1 of 1

Table 14.2.2.9.2: Comparison of cumulative incidence of Disease-related mortality at 3 years after start of investigational treatment between SCT and ContRuxo - Full Analysis Population

Timepoint	Treatment arm	Absolute difference in CIF	95% Lower confidence interval for absolute difference	95% Upper confidence interval for absolute difference	Z-value	P-value
3 years	ContRuxo	0.078	-0.167	0.324	0.626	0.532
	SCT					

CIF: Cumulative incidence function. ContRuxo: Ruxolitinib continuous therapy. SCT: Allogeneic stem cell transplantation. Disease-related mortality defined as presence of relapse and occurence of death.
3 years defined as 3 years + 92 days after the date of inclusion to allow for Ruxolitinib induction period. All numerical values are rounded to 3 decimal places.

Page 1 of 1